Olatinib is a novel JAK inhibitor that also inhibits the function of JAK1 dependent cytokines in some anti allergic, inflammatory, and itch responses. Research has confirmed that experimental animals (dogs) taking oral doses of 0.4-0.6mg/kg twice a day are safe and effective in treating itching caused by atopic dermatitis, and exhibit better therapeutic effects than oral corticosteroids such as prednisolone. During treatment, olatinib can alleviate itching within 24 hours, and over 70% of experimental animals experienced a reduction of over 50% in itching on the 7th day. Currently, Olatinib has been approved by the US FDA in 2013 to control itching and atopic dermatitis caused by canine allergic dermatitis. However, although Olatinib has a good therapeutic effect on allergic skin diseases in pet dogs, its scope of action is narrow. On the one hand, it has little effect on cytokines that do not participate in activating JAK1. On the other hand, its effect on allergic reactions ultimately only manifests in inhibiting degranulation of mast cells, i.e. the release of allergic mediators. It cannot directly block the binding of allergic mediators to related receptors, nor can it fundamentally block the occurrence and development of allergic skin diseases